Today: 7 February 2026
Subscribe
Browse Category

Biotech News News 14 January 2026 - 20 January 2026

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie shares fell 0.4% to $213.53 in early afternoon trading after phase III results for Epkinly showed a progression-free survival benefit but no statistically significant overall survival in lymphoma patients. The stock moved between $210.00 and $214.23 as investors looked ahead to the Feb. 4 earnings report and 2026 outlook.
20 January 2026
·····
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio shares jumped 24% to $6.82 midday Tuesday after the FDA gave guidance that could allow resubmission of its ANKTIVA bladder cancer drug without requiring a new clinical trial. The stock traded as high as $7.97 on heavy volume. The FDA requested more data but did not grant approval. ImmunityBio plans to submit additional information within 30 days.
20 January 2026
····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid. (Reuters) Why this matters now: AbbVie is hunting for fresh growth drivers as investors question the staying power of its lineup
18 January 2026
·······
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent revenue. Investors also received fresh insight on the company’s timeline for expanding ANKTIVA into a wider first-line bladder cancer market. ImmunityBio reported preliminary net product revenue of roughly $113 million for 2025 in a Friday release, with fourth-quarter revenue hitting
18 January 2026
·····
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

NEW YORK, Jan 18, 2026, 05:13 EST — Market closed ImmunityBio shares jumped sharply on Friday following a series of updates, including early sales figures for its approved bladder-cancer drug and new data from its development pipeline. The stock closed the day up 39.75% at $5.52 and later climbed to $6.04 in after-hours trading. (Yahoo Finance) This move is significant as ImmunityBio aims to show it can convert a high-profile approval into steady revenue, while expanding the narrative beyond its flagship drug, ANKTIVA. Investors, meanwhile, have favored biotech stocks with upcoming catalysts and more defined commercialization strategies—both of which ImmunityBio
18 January 2026
····
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

New York, Jan 17, 2026, 06:10 EST — Markets have closed for the day. Shares of ImmunityBio Inc (IBRX.O) surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of roughly 182 million shares. The rally is significant as ImmunityBio works to show ANKTIVA can shift from a niche debut to consistent commercial success. Investors are also focused on whether the drug can tap into a broader first-line bladder cancer
17 January 2026
·····
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

New York, January 16, 2026, 14:57 EST — Regular session Shares of BridgeBio Pharma Inc edged up 0.5% to $76.66 Friday afternoon, following the announcement of a $550 million convertible notes sale. The stock swung between $75.87 and $78.12, with roughly 5.9 million shares changing hands. (BridgeBio Investor Relations) This financing matters because it reshapes BridgeBio’s balance sheet in one go, extending maturities and cutting cash interest just as the company ramps up spending on commercialization and development. Convertible notes offer a well-known setup for equity holders. They’re debt instruments that can convert into shares down the line at a
16 January 2026
·····
ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

New York, January 16, 2026, 05:00 (EST) — Premarket ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia. (Business Wire) The update offers investors an early glimpse of how quickly ANKTIVA is growing commercially, ahead of the company’s audited annual results. It also provides fresh figures tied to the company’s expansion into new markets—the section traders have been eager to scrutinize in the filings. (Business Wire) ImmunityBio reported preliminary net product revenue of roughly
16 January 2026
····
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

New York, January 14, 2026, 14:54 EST — During regular session Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40. The move came after Praxis announced late Tuesday it hired epilepsy expert Dr. Orrin Devinsky for a new head of clinical strategy role. Steven Petrou, president of research and development, said Devinsky’s choice to join “reflects the strength of our scientific approach and long-term strategy.” (GlobeNewswire) Timing is crucial since investors zero in on regulatory filings that can shift a
14 January 2026
····
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

New York, Jan 14, 2026, 13:09 EST — Regular session Cogent Biosciences shares rose about 8% on Wednesday, lifting the biotech’s stock toward recent highs as investors focused on a near-term U.S. regulatory checkpoint for its lead drug candidate, bezuclastinib. The stock was up at $38.17, after trading between $35.17 and $38.34. The move matters because Cogent’s story is now dominated by filings and review clocks, not early-stage science. A clear path to FDA review — and a potential first launch — can reset how investors value a company that still has no marketed product. If the FDA accepts the
14 January 2026
·····
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

New York, January 14, 2026, 13:09 EST — Regular session underway. Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity treatments. CEO Brian Lian noted that interest was “broader than is visible” with more players “circling around the space.” Analysts put the potential market at $150 billion annually, and Pfizer’s $10 billion acquisition of Metsera last November has kept deal activity intense. (Reuters) The timing is key. The J.P. Morgan Healthcare Conference, an annual hotspot for merger chatter and biotech
14 January 2026
····
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

New York, Jan 14, 2026, 12:55 (EST) — Regular session Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline. The move matters because Edgewise is still pre-commercial, and its valuation hangs on when — and how cleanly — the next sets of data arrive. In biotech, dates can trade almost like earnings. Edgewise used the J.P. Morgan Healthcare Conference this week to tighten up its roadmap, giving investors a clearer sequence
14 January 2026
·····
1 2 3 4 … 12

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop